Upcoming Events There are no upcoming events at this time. News & Events Year All20232022202020192017 April 17, 2023Rapid Serial Killing of Target Cells by Vγ9Vδ2 T Cells in Cynomolgus Macaques and Humanized Mice Treated with a CD20-Directed Heterodimeric Butyrophilin 2A1/3A1 Fusion Protein January 7, 2022Phase 1 dose escalation of an agonist redirected checkpoint (ARC) fusion protein,SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas (NCT03894618) October 14, 2020Shattuck Labs Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares October 8, 2020Shattuck Labs Announces Pricing of Upsized Initial Public Offering September 1, 2020Shattuck Labs to Present at PEGS Summit 2020 August 31, 2020Shattuck Labs Announces Initiation of Phase 1 Clinical Trial of SL-172154 (SIRPα-Fc-CD40L) for the Treatment of Ovarian Cancer July 21, 2020Shattuck Labs Appoints Helen M. Boudreau to Board of Directors June 15, 2020Shattuck Labs Announces Closing of $118 Million Series B Financing February 25, 2020Shattuck Labs to Present at 40th Annual Cowen Health Care Conference February 18, 2020Shattuck Labs Promotes Dr. Taylor Schreiber to Chief Executive Officer February 4, 2020Taylor Schreiber to speak at the 2020 PEGS: The Essential Protein Engineering & Cell Therapy Summit, May 4-8, Boston, MA December 9, 2019Shattuck Labs Appoints Casi DeYoung as Chief Business Officer November 5, 2019Taylor Schreiber to speak at the 2020 CD47/Sirp a Summit – March 18-19th in Boston October 14, 2019Shattuck’s ARC platform October 7, 2019He Beat Lymphoma at 31, While Pioneering Breakthroughs in Cancer Research May 6, 2019Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L) August 10, 2017Takeda and Shattuck Labs Announce Collaboration to Explore ARC Fusion Proteins in Immuno-Oncology April 17, 2023Rapid Serial Killing of Target Cells by Vγ9Vδ2 T Cells in Cynomolgus Macaques and Humanized Mice Treated with a CD20-Directed Heterodimeric Butyrophilin 2A1/3A1 Fusion Protein January 7, 2022Phase 1 dose escalation of an agonist redirected checkpoint (ARC) fusion protein,SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas (NCT03894618) October 14, 2020Shattuck Labs Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares October 8, 2020Shattuck Labs Announces Pricing of Upsized Initial Public Offering September 1, 2020Shattuck Labs to Present at PEGS Summit 2020 August 31, 2020Shattuck Labs Announces Initiation of Phase 1 Clinical Trial of SL-172154 (SIRPα-Fc-CD40L) for the Treatment of Ovarian Cancer July 21, 2020Shattuck Labs Appoints Helen M. Boudreau to Board of Directors June 15, 2020Shattuck Labs Announces Closing of $118 Million Series B Financing February 25, 2020Shattuck Labs to Present at 40th Annual Cowen Health Care Conference February 18, 2020Shattuck Labs Promotes Dr. Taylor Schreiber to Chief Executive Officer February 4, 2020Taylor Schreiber to speak at the 2020 PEGS: The Essential Protein Engineering & Cell Therapy Summit, May 4-8, Boston, MA December 9, 2019Shattuck Labs Appoints Casi DeYoung as Chief Business Officer November 5, 2019Taylor Schreiber to speak at the 2020 CD47/Sirp a Summit – March 18-19th in Boston October 14, 2019Shattuck’s ARC platform October 7, 2019He Beat Lymphoma at 31, While Pioneering Breakthroughs in Cancer Research May 6, 2019Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L) August 10, 2017Takeda and Shattuck Labs Announce Collaboration to Explore ARC Fusion Proteins in Immuno-Oncology Sign up for Our Newsletter Notice: JavaScript is required for this content. Get in Touch Contact Us
